DG Capital Management LLC Decreases Stock Holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC)

DG Capital Management LLC decreased its holdings in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) by 26.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,114,692 shares of the company’s stock after selling 407,512 shares during the period. Fennec Pharmaceuticals makes up about 2.4% of DG Capital Management LLC’s holdings, making the stock its 9th largest holding. DG Capital Management LLC’s holdings in Fennec Pharmaceuticals were worth $7,045,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Franklin Resources Inc. lifted its stake in Fennec Pharmaceuticals by 18.7% in the third quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock worth $74,000 after purchasing an additional 2,330 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Fennec Pharmaceuticals by 31.6% in the fourth quarter. Wells Fargo & Company MN now owns 13,152 shares of the company’s stock worth $83,000 after buying an additional 3,155 shares during the period. Geode Capital Management LLC boosted its holdings in Fennec Pharmaceuticals by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 303,090 shares of the company’s stock valued at $1,916,000 after acquiring an additional 3,792 shares during the period. Rhumbline Advisers grew its position in Fennec Pharmaceuticals by 12.9% during the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company’s stock worth $217,000 after acquiring an additional 3,911 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Fennec Pharmaceuticals by 10.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company’s stock worth $386,000 after purchasing an additional 5,694 shares during the period. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $6.66, for a total value of $66,600.00. Following the completion of the transaction, the director now owns 76,294 shares of the company’s stock, valued at approximately $508,118.04. The trade was a 11.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 31,186 shares of company stock valued at $195,089 over the last ninety days. 10.98% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on FENC. Wedbush restated an “outperform” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, March 11th.

Fennec Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ FENC opened at $5.21 on Tuesday. The company has a 50 day moving average of $6.49 and a 200 day moving average of $5.73. Fennec Pharmaceuticals Inc has a twelve month low of $3.96 and a twelve month high of $11.11. The firm has a market cap of $143.73 million, a P/E ratio of -52.09 and a beta of 0.32.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.